In June 2012, this biomarker received FDA approval for use in detecting PCa in male individuals 50 years of age or older who had PSA levels of 4–10 μg/L and had undergone a digital rectal examination (DRE) without abnormal outcomes. The gene discussed is KLK3; the disease is posterior cortical atrophy.